COVID-19 Hits Sales Of Biogen Biosimilars Portfolio

As Firm Eyes Tecfidera US Landscape

 
• By Dean Rudge
  
Arrows
Biogen's biosimilars sales fell in Q2 following a Q1 boost • Source: Shutterstock

More from Biosimilars

More from Products